CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 278 enrolled
Drug / intervention
Morphine Group +2 moredrug
Likely dose
Morphine Group 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03431285
NCT03431285N/ACompleted
CompareCT.gov

Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control Trial

Imam Abdulrahman Bin Faisal University·interventional·Posted Feb 13, 2018·Updated May 28, 2025

In Brief

A clinical study evaluating Morphine Group, Ketamine Group, and 1 other intervention for Sickle Cell Crisis. Completed, enrolled 278 participants across 1 site.

Detailed Summary

Investigators hypothesize that administration of ketamine for pain relief in sickle cell patients with vaso-occlusive crisis early on will lead to a more rapid improvement in pain score and less narcotic requirement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Crisis
CountriesSaudi Arabia
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 13, 2018
Enrollment StartJan 1, 2018
Primary CompletionJan 10, 2019
Study CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 8.4 years ago

Interventions

Morphine Groupdrug

Patients will receive standard dose of morphine (0.1 mg/kg) in 100 ml normal saline infused over 30 min in addition to standard IV hydration.

Ketamine Groupdrug

Patients will receive low dose ketamine 0.3 mg/kg in 100ml N.S. infused over 30 min in addition to standard IV hydration

standard IV hydrationother

IV hydration as per our institutional protocol (Lactated Ringer's or NaCl 0.9% solution will be infused at a rate of 2-3 ml/kg/h)